- Company/Commercial (417)
- Corporate (357)
- Litigation / Dispute Resolution (292)
- Regulatory and compliance (240)
- Banking / Finance (222)
- Information Technology (155)
- Tax (148)
- Financial services (131)
- Employment (113)
- Intellectual Property (109)
- Real Estate (103)
- Funds (95)
- Healthcare (87)
- Energy (69)
- Commodities (67)
- Media/Entertainment/Sport (56)
- Crime (51)
- Clinical/Medical Negligence (45)
- Business Tax (43)
- Insurance/reinsurance (42)
- Environment (41)
- Construction (40)
- PPP/PFI/Commercial projects (40)
- Privacy and reputation (36)
- Pharma/Biotech (33)
- Insolvency & restructuring (32)
- Transport (Including aviation and shipping) (28)
- Private Equity (25)
- Telecoms (25)
- Licensing/Gaming/Betting (23)
- Competition/EU (21)
- Human Rights (21)
- Charities (17)
- Public Sector/Local Authority (16)
- Planning (15)
- Family (10)
- Pensions (9)
- Travel and Tourism (9)
- Personal tax / Trusts (8)
- Agriculture (6)
- Professional Indemnity/Negligence (6)
- Immigration (5)
- In-House (2)
- Other (2)
- Personal Injury (1)
- Private Client (1)
Sort By: Newest first | Oldest first
Cushman & Wakefield is to acquire Massey Knakel Realty Services, advised by DLA Piper.
DLA Piper is assisting InterContinental Hotels Group in its acquisition of boutique hotel operator Kimpton Hotels & Restaurants.
DLA Piper has advised Market Tech Holdings on its £750m AIM IPO – the biggest of the year.
DLA Piper has advised on the largest LIC IPO on the Australian Securities Exchange since late 2006.
DLA Piper’s Mark Radcliffe, a Silicon Valley-based partner, has been chosen as one of 25 recipients of The Recorder’s first-ever ‘Innovator Award’.
DLA Piper has advised Aviva on the disposal of a distressed portfolio of 180 mixed-use properties located across the UK to KWE for £503m.
DLA Piper has advised Market Tech Holdings, a holding company with iconic real-estate assets in London’s Camden Town, on its £750m AIM IPO.
DLA Piper’s role encompassed a full due diligence review of the target group, advice on the auction process and subsequent completion of the acquisition.
Health Alert — Julia Clare v Australian Community Pharmacy Authority; Dr Reid v Medical Council of NSW; and more
DLA Piper has released the 22 December 2014 issue of its Health Alert, which focuses on judgments, legislation and reports in the health sector.
The European Court of Justice (CJEU) has handed down a landmark judgment concerning the patentability of stem cells in Europe.
A well-known British performing artist was granted permission to take his case to the Supreme Court, where he will appeal the Court of Appeal’s decision in OPO v MLA & STL.
The increased focus of national data protection authorities on the processing of personal data through mobile apps was again confirmed in an open letter from a group of data protection authorities.
Global Insight — Spanish insolvency laws; retention of title in the UK; portfolio transactions; and more
Global Insight is a digital publication bringing you news, views and analysis from DLA Piper’s global restructuring group.
The European Union member states are preparing to introduce a new European Patent with Unitary Effect and a single Unified Patent Court with divisions located throughout Europe.
California’s Insurance Fraud Prevention Act: three unsettled issues the health sector should understand
California’s Insurance Frauds Prevention Act, Ins. Code §§ 1871 et seq. (IFPA), is an unusual false claims statute.
Patents directed to genetic material have been the subject of significant public discourse and legal challenge worldwide.
A court ruled in the case of a plaintiff who claimed his privacy rights had been violated because Google search engine results of his name included news articles suggesting he had a criminal past.
This briefing from DLA Piper discusses three key intellectual property and technology cases: Kimble v Marvel Enterprises, B&B Hardware, inc v Hargis Industries and Teva Pharmaceuticals v Sandoz.
The Supreme Court ruled in FTC v Actavis that settlement agreements for patent infringement suits between branded and generic drug companies are not immune from antitrust scrutiny.
Arguably, Germany is the jurisdiction that has the most to lose with the introduction of the UPC.